Amedica and Celling Biosciences to Partner on Biologically Enhanced Spinal Fusion Devices

Amedica Corporation (NASDAQ:AMDA) announced a collaboration with Celling Biosciences, a leader in autologous cellular therapy technologies, to research and develop biologically enhanced implants. As part of the initial phase of the collaboration, Celling Biosciences’ team of scientists produced research indicating mesenchymal stem cells can be optimized and proliferate when using silicon nitride compared to the current PEEK and titanium biomaterial standards.
According to the news release:

Results from the recent in vivo scientific study show that Amedica’s proprietary silicon nitride composition significantly outperformed PEEK in attachment testing of mesenchymal stem cells. Amedica’s unique silicon nitride biomaterial contains natural nano-surface topography and chemistry that play an active role in implant integration, which current trends in surface modification efforts have not replicated.  The results of the study suggest the microenvironment of silicon nitride promotes better cell adhesion and compatibility with five times greater cell adhesion as compared to the PEEK material used.

Mr. Kevin Dunworth, Chief Executive Officer of Celling Biosciences commented:

As an industry, we continue to strive for innovation beyond current standards and Celling Biosciences has always focused on innovating standards of the future. Current trends show many evolutions of surface modifications and surface treatments around PEEK and titanium, but we believe Amedica’s proprietary technology is the future progression of biologically enhanced implants. Coupled with our ability to process tissue and apply those cells to cell-centric materials, such as silicon nitride, we look forward to further collaboration and optimizing the environment for healing.

Click here to view the full press release.